Introduction {#s1}
============

During embryo development, sharp borders form at the interface of adjacent tissues and between domains within tissues that have a different regional identity. These borders are generated by cell segregation mechanisms that establish and maintain a precise organisation of tissues ([@bib4]; [@bib18]; [@bib24]). At some borders, a distinct boundary cell population is induced which serves as a signaling centre that regulates the patterning of cell differentiation within the tissue. The formation of a sharp and straight border enables such boundary signaling cells to be correctly organised ([@bib19]). It remains unclear whether or how the induction of a signaling centre is coordinated with border sharpening. In principle, border sharpening and formation of boundary signaling cells may involve parallel mechanisms that are not directly linked. However, studies of the vertebrate hindbrain found that Eph receptor and ephrin signaling is required both for border sharpening and the formation of boundary cells ([@bib16]; [@bib77]; [@bib92]), raising the possibility that there is a mechanistic link.

Eph receptor and ephrin signaling has major role in cell segregation and border sharpening in many tissues in vertebrates ([@bib4]; [@bib7]; [@bib25]). Eph receptors comprise a large family of receptor tyrosine kinases that are activated upon binding to their membrane-bound ephrin ligands. Members of the EphA subclass bind to the GPI-anchored ephrinA ligands, whereas EphB receptors bind to transmembrane ephrinB ligands; an exception is EphA4 which binds to ephrinA and specific ephrinB family members ([@bib29]). Upon interacting through cell-cell contact, Eph receptor and ephrin proteins are clustered and this activates signal transduction through both components, termed forward and reverse signaling, respectively ([@bib49]; [@bib62]). For Eph receptors, this involves kinase-dependent signaling that activates multiple intracellular pathways. In addition, signaling is mediated by a motif at the C-terminus of Eph receptors that binds to PDZ domain proteins. In the case of ephrinB proteins, signaling occurs through phosphorylation of conserved tyrosine residues by cytoplasmic kinases, and also through interaction of PDZ domain proteins.

Eph receptors and ephrins that have a high affinity for each other are expressed in complementary domains in many tissues ([@bib7]; [@bib29]; [@bib69]), such that activation of forward and reverse signaling occurs at the interface. Eph receptor and ephrin signaling can drive cell segregation and border sharpening through multiple mechanisms that likely depend upon whether the tissue is epithelial or mesenchymal: by decreasing cell-cell adhesion ([@bib23]; [@bib72]), by increasing cortical tension ([@bib5]; [@bib6]), or by triggering cell repulsion ([@bib65]; [@bib68]; [@bib76]; [@bib89]). In addition, Eph-ephrin signaling has been found to regulate cell differentiation in a number of tissues (reviewed by [@bib51]; [@bib88]). The regulation of cell differentiation and segregation may be distinct and context-dependent functions. Alternatively, Eph-ephrin signaling could couple cell specification to maintenance of their organisation. For most tissues, it is unclear whether such coupling occurs, but a potential example is the formation of boundaries in the vertebrate hindbrain.

The hindbrain is subdivided into segments, termed rhombomeres (r1-r7), each with a distinct anteroposterior identity and demarcated by borders across which cell intermingling is restricted ([@bib27]). These borders are initially fuzzy and then sharpened through the regulation of cell identity ([@bib1]; [@bib85]) in combination with cell segregation driven by Eph-ephrin signaling ([@bib16]; [@bib42]; [@bib46]; [@bib57]; [@bib92]; [@bib93]). Boundary cells are induced to form at segment borders ([@bib35]) and express specific molecular markers that distinguish them from non-boundary cells ([@bib13]; [@bib16]; [@bib39]; [@bib92]). In zebrafish, these include the Notch modulator, *rfng*, which by inhibiting neurogenesis promotes the maintenance of boundary cells ([@bib13]). Boundary cells are a source of neuronal progenitor cells in chick ([@bib63]), and express a number of signaling molecules that may regulate local patterning ([@bib2]; [@bib31]; [@bib66]; [@bib70]; [@bib86]). In the zebrafish hindbrain, boundary cells organise spatially-restricted neurogenesis within segments by expressing Semaphorin chemorepellants that position fgf20-expressing neurons in each segment centre ([@bib33]; [@bib77]). Clues to how boundary cells are induced at segment borders have come from studies of Eph receptor and ephrin function. Several Eph receptors are segmentally expressed in the hindbrain, in a complementary pattern to ephrinBs that they have high affinity for: *ephA4* in r3 and r5 is complementary to *ephrinB3* in r2, r4 and r6; *ephB4* in r2, r5 and r6 is complementary to *ephrinB2* in r1, r4 and r7. Disruption of Eph receptor or ephrin function leads to a decrease both in the sharpening of segment borders and in the expression of boundary markers ([@bib16]; [@bib70]; [@bib77]; [@bib92]). These findings raise the questions of how Eph-ephrin signaling leads to boundary cell formation and whether this involves distinct pathways from border sharpening.

We set out to dissect mechanisms of signaling that underlie border sharpening and boundary cell specification in the zebrafish hindbrain. EphA4 and ephrinB3 act as a signaling pair since knockdown of either component disrupts the same segment boundaries ([@bib77]). We find that boundary cell markers are expressed in *epha4*-expressing cells and are up-regulated by forward signaling. By creating a series of truncation and point mutants in *epha4*, we show that kinase-dependent and PDZ domain-dependent signaling both contribute to regulation of border sharpening and boundary-specific gene expression. We find that boundary marker expression is regulated by myosin II phosphorylation that occurs downstream of EphA4 activation and increases mechanical tension at segment borders. Mechanotransduction that induces boundary marker expression is mediated by nuclear translocation of Taz. The regulation of actomysosin contraction by Eph signaling thus couples the maintenance of sharp borders and induction of a boundary signaling centre.

Results {#s2}
=======

Boundary marker expression occurs in ephA4-expressing cells {#s2-1}
-----------------------------------------------------------

Since *epha4* (*epha4a*) is expressed in r3 and r5 ([@bib92]), and *ephrinb3* (*efnb3b*) in r2, r4 and r6 ([@bib10]), this Eph-ephrin pair interacts at all borders of r3 and r5. Due to the bidirectionality of activation, knockdown of either component will lead to loss of both Eph and ephrin activation, and it is therefore not possible to deduce whether forward and/or reverse signaling regulates boundary marker expression. A clue can come from determining whether boundary cells form in *epha4*-expressing cells, *ephrinb3*-expressing cells, or both. To address this, we carried out in situ analysis using the hybridisation chain reaction (HCR) which enables sensitive fluorescent detection of multiple transcripts ([@bib14]). We found that *rfng* expression which marks hindbrain boundary cells occurs in *epha4*-expressing cells at the borders of r3 and r5 ([Figure 1A,B,C--C''](#fig1){ref-type="fig"}). *rfng* expression is also detected in a few cells that are not expressing *epha4*, which are most consistently found at the lateral edge of the r5/r6 border (arrow in [Figure 1A,B](#fig1){ref-type="fig"}). We also analysed expression of *wnt1*, which is expressed in the roof plate and in the dorsal part of hindbrain boundaries ([Figure 1D](#fig1){ref-type="fig"}). We found that *wnt1* expression in boundaries also occurs predominantly in *epha4*-expressing cells ([Figure 1E,F](#fig1){ref-type="fig"}). Boundary cell formation thus occurs in cells in which forward signaling is occurring. However, *rfng* expression also occurs in some cells that are not expressing *epha4*, which could reflect a role of reverse signaling, or a dynamic relationship between *epha4* and *rfng* gene expression.

![Boundary markers are expressed in epha4-expressing rhombomeres.\
(**A--C**) HCR stainings for *rfng* and *epha4. rfng* is mainly expressed in *epha4*-expressing cells in rhombomeres r3 and r5, with a few *rfng-*expressing cells in adjacent segments, for example r6 (arrowhead). (**C--C''**) show a higher magnification view of an r2/r3 border. (**D--F**) Boundary expression of *wnt1* is dorsal to *rfng* (**D**) and is co-expressed with epha4 (**E, F**). (**A--C, E, F**) are dorsal views, (**D**) is a lateral view, dorsal (**d**) top, ventral (**v**) bottom. Anterior to the left in all panels. Scale bar: 50 μm.](elife-49696-fig1){#fig1}

Border sharpening and boundary marker expression require forward signaling {#s2-2}
--------------------------------------------------------------------------

Knockdown of *epha4* or *ephrinb3* leads to loss or decrease in expression of boundary cell markers at three borders where they interact ([Figure 2A](#fig2){ref-type="fig"}): r2/r3, r3/r4 and r5/r6 ([@bib77]); there is potential functional redundancy with *ephb4* and *ephrinb2* at the r4/r5 border ([@bib10]; [@bib15]; [@bib16]). To test roles of different aspects of EphA4 signaling, we used CRISPR/Cas9 genome modification to create a series of zebrafish lines with point or truncation mutations, depicted in [Figure 2B](#fig2){ref-type="fig"} (sequences in [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). The null mutant has a 4 bp deletion which terminates EphA4 protein within the ligand-binding domain. The truncation mutant terminates the protein at residue 651 (*epha4^Δ651^*), deleting most of the tyrosine kinase domain and all C-terminal domains, and thus completely lacks forward signaling but potentially still activates reverse signaling. The kinase-dead mutant (*ephA4^KD^*) replaces a lysine residue essential for kinase function with methionine. The *epha4^ΔPDZBD^* mutant is truncated at residue 994 which removes the five C-terminal amino acids containing the PDZ binding domain (PDZBD) motif.

![EphA4 forward signalling regulates boundary marker expression and cell segregation.\
(**A**) Schematic representation of the segmented expression of EphA4 and ephrinB3 in the hindbrain. (**B**) Schematic representation of the different mutant alleles of *ephA4a* generated for this study. The null allele contains an early truncation in the ligand binding domain. The *epha4^Δ651^* allele lacks most of the cytosolic domain. The *ephA4^KD^* allele contains a point mutation of a critical lysine in the tyrosine kinase domain. The *ephA4^ΔPDZBD^* mutation consists of a C-terminal truncation that deletes the PDZ-binding domain. LBD -- ligand binding domain; CRD -- cysteine rich domain; FN -- fibronectin repeat; TK -- tyrosine kinase domain; SAM -- sterile alpha motif; PDZBD -- PDZ binding domain. (**C--H**) *rfng* is expressed at boundaries in control embryos (arrowheads) (**C**), but is reduced or absent (asterisk) at specific boundaries in *ephrinb3^-/-^* (**D**), *epha4^-/-^* (**E**), *epha4^Δ651^* (**F**), *epha4^KD^* (**G**) and *epha4^ΔPDZBD^* (**H**) mutants. Numbers analysed for C-G are in [Figure 4](#fig4){ref-type="fig"} legend. For H, 8/8 have decrease at r2/r3, 4/8 at r5/r6. (**I--N**) *egr2* expression in r3 and r5 has sharp borders in control embryos (I, 13/13); border sharpening defects (arrowheads) are observed in *ephrinb3^-/-^* (J; 12/12), *epha4^-/-^* (K; 17/17), *epha4^Δ651^* (L; 8/8), *epha4^KD^* (M; 6/6) and *epha4^ΔPDZBD^* (N; 2/7 at r2/r3; 7/7 at r5/r6) mutants. Dorsal views, anterior to the top in all panels. Scale bar: 50 μm.](elife-49696-fig2){#fig2}

We found that the null mutant of *epha4* has the same phenotype described previously for *epha4* knockdown, with loss of *rfng* expression at the r2/r3, r3/r4 and r5/r6 borders ([Figure 2E](#fig2){ref-type="fig"}; compare with wild type, [Figure 2C](#fig2){ref-type="fig"}). Furthermore, expression of other boundary markers, including *wnt1* and *sema3gb*, was disrupted at these borders ([Figure 2---figure supplement 2A--F](#fig2s2){ref-type="fig"}). A milder disruption of *rfng* expression at the r2/r3, r3/r4 and r5/r6 borders is found in *ephrinB3* null mutant embryos ([Figure 2D](#fig2){ref-type="fig"}), likely reflecting some functional overlap with *ephrinB2* which is also a ligand for EphA4 ([@bib16]). The *epha4^Δ651^* truncation mutant was found to have the same loss of *rfng* expression as *epha4* null mutants ([Figure 2F](#fig2){ref-type="fig"}), supporting the idea that boundary cell formation is dependent upon EphA4 forward signaling. However, since loss of the cytoplasmic domain of EphA4 might alter its activity as a ligand, this finding does not rule out a contribution of reverse signaling. To address whether kinase-dependent forward signaling is required, we analysed the *epha4^KD^* mutant and found a major decrease, but not complete loss of *rfng* expression at the r2/r3, r3/r4 and r5/r6 borders ([Figure 2G](#fig2){ref-type="fig"}). The residual *rfng* expression at the r5/r6 border occurs in *epha4*-expressing cells ([Figure 2---figure supplement 2G,G'](#fig2s2){ref-type="fig"}), arguing against the possibility that it is due to reverse signaling activated by *epha4^KD^*. The presence of some *rfng* expression at segment borders in the *epha4^KD^* mutant suggests that kinase-independent signaling contributes to boundary cell formation. To test whether there is a parallel pathway involving signaling through PDZ domain proteins, we analysed the *epha4^ΔPDZBD^* mutant. We found that there is a mild decrease in *rfng* expression at the r2/r3 and r5/r6 borders, though not at the r3/r4 border ([Figure 2H](#fig2){ref-type="fig"}). These findings are consistent with a contribution of PDZBD-dependent signaling to boundary cell formation.

Analysis of *egr2* expression in the e*pha4* null mutant revealed a decrease in sharpness of the r2/r3, r3/r4 and r5/r6 borders, with some *egr2*-expressing cells in the adjacent segments ([Figure 2K](#fig2){ref-type="fig"}; compare with control, [Figure 2I](#fig2){ref-type="fig"}). The sharpness of the same borders was disrupted in the *ephrinb3*, *epha4^Δ651^* and *epha4^KD^* mutants, though with fewer ectopic *egr2*-expressing cells compared with the null mutant ([Figure 2J,L,M](#fig2){ref-type="fig"}). In the *epha4^ΔPDZBD^* mutant there was a decrease in sharpness at the r5/r6 border but only in 30% of the embryos at r2/r3 ([Figure 2N](#fig2){ref-type="fig"}). Taken together, these findings suggest that both kinase-dependent and PDZ domain-dependent pathways contribute to upregulation of boundary marker expression, with a stronger input of kinase signaling. There is a correlation between decreased border sharpness and decreased boundary marker expression, suggestive of a mechanistic link.

Boundary marker expression is regulated by myosin phosphorylation {#s2-3}
-----------------------------------------------------------------

These findings raise the question of how EphA4 forward signaling leads to *rfng* expression at boundaries. EphA4 signaling regulates formation of an actin cable at boundaries, which is first detected at 15 hpf and has been implicated in maintenance of a straight border through actomyosin-dependent generation of cortical tension ([@bib5]). Hindbrain boundary cells have a distinct shape from non-boundary cells, which is altered by knockdown of the myosin phosphatase regulator, *mypt1*, that leads to increased phosphorylation of myosin light chain (pMLC) and actomyosin contraction ([Figure 3H](#fig3){ref-type="fig"}) ([@bib36]). Consistent with these findings, we found a higher level of pMLC co-localising with the actin cable at hindbrain borders ([Figure 3A,B](#fig3){ref-type="fig"}). Furthermore, pMLC was no longer detected at the r2/r3, r3/r4 and r5/r6 borders in *epha4* null mutants ([Figure 3C,D](#fig3){ref-type="fig"}). Surprisingly, we found that knockdown or transient CRISPR/Cas9-mediated knockout of *mypt1* leads to an increase in the level and width of *rfng* expression at hindbrain boundaries ([Figure 3E--G](#fig3){ref-type="fig"}). Likewise, *mypt1* knockdown leads to increased expression of *wnt1* and *sema3gb* at boundaries ([Figure 3---figure supplement 1A--D](#fig3s1){ref-type="fig"}). We wondered whether the broader expression of *rfng* after *mypt1* knockdown occurs in regions of forward and/or reverse signaling. By carrying out in situ HCR we found that *rfng* expression spreads only into the *epha4*-expressing domain where forward signaling is occurring ([Figure 3I--L](#fig3){ref-type="fig"}). The increased boundary marker expression after *mypt1* knockdown suggests that actomyosin contraction regulates boundary cell formation. To test this, we treated embryos at different time intervals with blebbistatin, an inhibitor of myosin II ATPase activity. We found that blebbistatin treatment from 15 hpf onwards strongly disrupts the upregulation of *rfng* expression at boundaries, with a progressively milder effect on the expression when the treatment is started at later times, and no change detected when treated from 18 hpf ([Figure 3M--P](#fig3){ref-type="fig"}). Furthermore, disruption of actin polymerisation by treating embryos with latrunculinB leads to loss of *rfng* expression at boundaries ([Figure 3---figure supplement 1E,F](#fig3s1){ref-type="fig"}).

![Actomyosin tension regulates boundary expression of *rfng.*\
(**A, B**) Immunostainings to detect actin (**A**) and pMLC (**B**) which co-localize at segment boundaries. (**C, D**) pMLC is detected at all boundaries in control embryos (C, 37/38) but not at r2/r3, r3/4 and r5/r6 boundaries in *epha4^-/-^* embryos (D, 24/24). Lateral views, anterior to the left. (**E--G**) *rfng* expression is increased in *mypt1* knockdowns (F; 38/45) and embryos injected with CRISPR/Cas9 against *mypt1* (G; 19/26), compared to controls (E; 37/38). (**H**) Depiction of Mypt1 regulating actomyosin tension by dephosphorylating pMLC. (**I--L**) HCR stainings reveal that *rfng* expression in *epha4*-expressing cells in control embryos (I, J; 24/24) is increased after knockdown of *mypt1* (K, L; 28/36). (**M--P**) Myosin II inhibitor blebbistatin suppresses *rfng* transcription when treatment is initiated at 15 hpf (M; 21/21), 16 hpf (N; 25/25) or 17 hpf (O; 23/23), but it is less affected when initiated at 18 hpf (P; reduced in 8/22). (**E--P**) Dorsal views, anterior to the top. Scale bar: 50 μm.](elife-49696-fig3){#fig3}

These findings suggest that the induction of hindbrain boundary markers involves increased actomyosin contraction downstream of EphA4 forward signaling. We therefore wondered whether *mypt1* knockdown can rescue the decrease in *rfng* expression that occurs in *epha4* mutants. We found that *mypt1* knockdown in *epha4* null mutants rescues *rfng* expression at the r2/r3 and r3/4 borders, but not at the r5/r6 border ([Figure 4C,H](#fig4){ref-type="fig"}; wild type embryos in [Figure 4A,F](#fig4){ref-type="fig"}; quantitated in [Figure 4K](#fig4){ref-type="fig"}). This suggests that *mypt1* knockdown is increasing residual MLC phosphorylation at the r2/r3 and r3/4 borders in the *ephA4* null mutant, potentially due to other segmentally-expressed Eph receptors, whereas such compensation does not occur at the r5/r6 border. Intriguingly, *mypt1* knockdown rescues *rfng* expression at the r5/r6 border as well as the r2/r3 and r3/r4 borders in the *epha4^Δ651^* and *epha4^KD^* mutants ([Figure 4D,E,I--K](#fig4){ref-type="fig"}). This finding suggests that there is some compensation with mutants that have the EphA4 extracellular domain that does not occur when EphA4 protein is completely absent. *mypt1* knockdown rescues *rfng* expression at all hindbrain boundaries in *ephrinB3* null mutants ([Figure 4B,G](#fig4){ref-type="fig"}), consistent with residual EphA4 activation by other ephrins.

![Increased tension selectively restores boundary expression of *rfng* in *epha4* and *ephrinb3* mutants.\
(**A--K**) Knockdown of *mypt1* increases *rfng* expression at hindbrain boundaries in control embryos (**F**) and restores *rfng* expression at specific boundaries in *ephrinb3^-/-^* (**G**), *epha4^-/-^* (**H**), *epha4^Δ651^* (**I**) and *epha4^KD^* (**J**) mutants compared to uninjected controls (**A--E**). (**K**) Percentage of embryos showing *rfng* expression at the different boundaries for: control (n = 38); *MO-mypt1* (45); *epha4a^-/-^* (13); *epha4a^-/-^MO-mypt1* (42); *efnb3b*^-/-^ (14); *efnb3b*^-/-^ *MO-mypt1* (17); *epha4a^Δ651^* (15); *epha4a^Δ651^ MO-mypt1* (22); *epha4a^KD^* (13); *epha4a^KD^ MO-mypt1* (27). Dorsal views, anterior to the top. Arrowheads indicate normal boundary expression of *rfng*, while asterisks indicate reduction or absence of *rfng* expression at boundaries. Scale bar: 50 μm.](elife-49696-fig4){#fig4}

taz and tead1a are required for boundary marker expression {#s2-4}
----------------------------------------------------------

Taken together, these findings suggest a model in which EphA4 forward signaling leads to actomyosin contraction that induces boundary marker expression. This raises the question of what pathway links mechanical tension to gene regulation at hindbrain boundaries. To address this, we carried out morpholino-mediated knockdowns of genes that have been implicated in mechanotransduction in other contexts. This screen revealed that knockdown of the *taz* gene disrupts boundary marker expression, including *rfng*, *wnt1* and *sema3gb* ([Figure 5A,B,H](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1A--D](#fig5s1){ref-type="fig"}). To test the specificity of the gene knockdown, we carried out transient CRISPR/Cas9-mediated deletions of *taz* and found that this also leads to decreased *rfng* expression at boundaries ([Figure 5C,H](#fig5){ref-type="fig"}). In contrast, knockdown or knockout of the related *yap1* gene has little effect on boundary marker expression ([Figure 5D,E,H](#fig5){ref-type="fig"}), albeit this could reflect that loss of function is not complete. The strong effect of *taz* loss of function suggests that it has a non-redundant role in upregulation of boundary marker expression.

![Taz and Tead1a are required for boundary expression of *rfng*.\
(**A--H**) Hindbrain boundary expression of *rfng* is reduced in *taz* knockdowns (**B**), and in *taz* (**C**) and *tead1a* (**F**) transient knockouts compared to controls (**A**), while *yap1* knockdown (**D**) and *yap1* (**E**) and *tead3a* (**G**) transient knockouts have normal *rfng* expression. (**H**) Scoring of boundary expression of *rfng* in different conditions according to severity levels: wild type = normal expression of *rfng* in all boundaries; severity 1 = general reduction of *rfng* expression levels; severity 2 = partial absence of *rfng* expression leading to discontinuous boundaries; severity 3 = total absence of *rfng* boundary expression. Number of embryos: control (15); MO-*taz* (20); CRISPR-*taz* (30); MO-*yap1* (52); CRISPR-*yap1* (21); CRISPR-*tead1a* (23); CRISPR-*tead3a* (12). Dorsal views, anterior to the top. Scale bar: 50 μm.](elife-49696-fig5){#fig5}

Taz and Yap have been intensively studied as components of a pathway which links mechanical tension to the regulation of cell proliferation ([@bib21]; [@bib30]; [@bib37]; [@bib53]). In addition, Taz and Yap have been implicated in the maintenance of stem cells or regulation of cell differentiation in specific tissues ([@bib12]; [@bib43]; [@bib54]; [@bib55]; [@bib61]; [@bib83]). Mechanical cues or other inputs lead to the translocation of Yap/Taz protein from cytoplasm to the nucleus, where they can interact with Tead family transcription factors to regulate specific gene expression. Gene expression studies have found that two tead family members, *tead1a* and *tead3*, are widely expressed in the nervous system, with segmental regulation of the level of expression ([@bib79]). To determine whether Taz acts together with these Tead family transcription factors to regulate boundary gene expression, we carried out transient Crispr-mediated knockouts. We found that knockout of t*ead1a*, but not of *tead3*, leads to a decrease in *rfng* expression ([Figure 5F--H](#fig5){ref-type="fig"}). Since the decrease in *rfng* expression was less than occurs following *taz* knockout, there may be partial redundancy with other *tead* family members.

Myosin regulation downstream of EphA4 regulates Taz localisation {#s2-5}
----------------------------------------------------------------

To determine whether EphA4 signaling and actomyosin contraction acts by regulating the subcellular localisation of Taz protein, we first carried out immunostaining studies during normal hindbrain development. We found an increased level of Taz, accompanied by nuclear localisation in some cells, at hindbrain boundaries, starting at 14 hpf and becoming more prominent at 18 hpf ([Figure 6A--C,J](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Since not all cells at boundaries have nuclear Taz, there may be a dynamic regulation of subcellular localisation. These observations are consistent with evidence that the actin cytoskeleton can regulate the stability as well as nuclear localisation of Taz ([@bib20]). To determine whether Taz localisation is regulated downstream of EphA4, we carried out immunostaining in *epha4* null mutants. We found that there is no longer nuclear Taz staining at the r2/r3, r3/r4 and r5/r6 borders, whereas the increased level of Taz and nuclear localisation remains at the r1/r2, r4/5 and r6/r7 borders, where boundary marker expression occurs in *epha4* mutants ([Figure 6D,K](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). To determine whether Taz localisation is regulated by forward signaling, we analysed *epha4^Δ651^* and *epha4^KD^* mutants and found that nuclear Taz was no longer detected at the r2/r3, r3/r4 and r5/r6 borders ([Figure 6E,F](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). These findings suggest that forward but not reverse signaling leads to nuclear translocation of Taz. To test whether Taz localisation is influenced by myosin phosphorylation, we carried out *mypt1* knockdown and found that this leads to an increase in the number of cells with nuclear Taz at segment borders ([Figure 6G,I,L](#fig6){ref-type="fig"}). This finding is consistent with the observation of an increased number of cells expressing *rfng* following *mypt1* knockdown. Finally, we analysed the effect of decreasing myosin II function by treating embryos with blebbistatin and found a decrease in nuclear localisation of Taz ([Figure 6H](#fig6){ref-type="fig"}).

![Eph-ephrin signalling and actomyosin tension regulate Taz nuclear localization.\
(**A--C**) Time course of the localization of Taz protein. Nuclear localization of Taz starts to be detected in hindbrain boundaries at 14 hpf (**A, A'**). Several boundaries have elevated nuclear Taz at 16 hpf (**B, B'**), and nuclear Taz is present in all boundaries at 18 hpf (**C, C'**). (**D--F**) Nuclear Taz is reduced at r2/r3, r3/r4 and r5/r6 boundaries in *epha4* null (**D, D'**), epha4*^Δ651^* (**E, E'**) and *epha4a^KD^* mutants (**F, F'**) at 18 hpf. (**G, G'**) Ectopic cells with elevated nuclear Taz are observed at 18 hpf after *mypt1* knockdown. (**H, H'**) Blebbistatin treatment inhibits the nuclear accumulation of Taz at boundaries. (**I**) Quantitation of number of nuclei with Taz staining in controls (n = 12) and *mypt1* knockdowns (n = 13) (\*\*\*\*p\<0.0001). (**J--L**) Higher magnification images corresponding to boxed areas in C', D' and G'. Dorsal views, anterior to the top. Arrowheads indicate boundary position; asterisks indicate boundaries with reduced nuclear Taz; brackets indicate expansion of nuclear Taz staining. Scale bar: 30 μm.](elife-49696-fig6){#fig6}

The *Drosophila* homologue of Yap/Taz, Yorkie, can increase myosin activity and tension independently of its function as a transcription co-factor ([@bib94]). We therefore wondered whether Taz is required for actomyosin regulation in the hindbrain. To address this question, we analysed MLC phosphorylation following knockout of Taz, and found that pMLC is still elevated at hindbrain boundaries ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Taken together, these findings support a model in which EphA4 activation leads to actomyosin phosphorylation and contraction at segment borders, which in turn increases nuclear localisation of Taz and boundary marker expression.

Discussion {#s3}
==========

A key concept that came from early studies of compartment boundaries is that sharp borders enable the correct organisation of signaling centres ([@bib19]). However, it remains unclear whether or how border sharpening and boundary cell formation are coordinated. We have studied this in the vertebrate hindbrain, in which segment borders are sharpened and boundary cells form that act as a signaling centre. We show that forward signaling of EphA4, which regulates myosin light chain phosphorylation that increases cortical tension, is required both for border sharpening and for hindbrain boundary cell formation. Furthermore, increasing myosin II phosphorylation by knockdown of *mypt1* increases boundary marker expression, whereas inhibition of myosin II function or actin polymerization blocks boundary marker expression. We show that EphA4 forward signaling and myosin phosphorylation induce nuclear translocation of Taz, which together with Tead1a regulates boundary marker expression ([Figure 7](#fig7){ref-type="fig"}). It is likely that activation of other Eph receptors underlies increased pMLC and boundary gene expression at the r1/r2, r5/r6 and r6/r7 borders that are not disrupted in the EphA4 mutants; for example, EphB4 which underlies cell segregation and has complementary expression to ephrinb2a ([@bib10]; [@bib15]; [@bib16]). Interestingly, the *rac3b* gene which is adjacent to *rfng* is co-regulated in hindbrain boundary cells, and knockdown of *rac3b* disrupts actomyosin cable formation and border sharpness ([@bib52]). Taken together with our findings, this suggests that Eph signaling initiates boundary gene expression by increasing actomyosin contraction, which is then maintained in a positive feedback loop through expression of *rac3b*. Since increased tension underlies the maintenance of a straight border ([@bib5]), cell segregation and boundary cell formation are coupled, thus ensuring that boundary cells are organised at a sharp border ([Figure 7](#fig7){ref-type="fig"}).

![Model of EphA4 signaling and hindbrain boundary cell induction.\
The diagram on the left depicts the activation of EphA4 forward signaling by ephrinB3, which through kinase-dependent and PDZ binding domain-dependent pathways increases the level of pMLC. pMLC promotes actomyosin contraction and translocation of Taz to the nucleus, where it interacts with Tead1a to upregulate boundary-specific gene expression. As a consequence, boundary cells form in EphA4-expressing cells at the borders of r3 and r5 (top right). By acting through pMLC, EphA4 signaling couples boundary cell formation to the maintenance of border sharpness (bottom right).](elife-49696-fig7){#fig7}

EphA4 signaling and boundary cell formation {#s3-1}
-------------------------------------------

By generating a series of point and deletion mutants of *epha4*, we find that forward signaling is essential for boundary marker expression, with a strong input of kinase-dependent signaling and lesser input of PDZ binding domain dependent signaling. These findings are consistent with studies of the regulation of cell repulsion and cortical tension by Eph receptor signaling ([@bib6]; [@bib23]; [@bib59]; [@bib68]; [@bib69]; [@bib76]). Cell repulsion and tension are regulated by increased Rho activity, which leads to myosin light chain phosphorylation and actomyosin contraction at borders where Eph receptor activation is occurring ([@bib23]; [@bib69]). Multiple kinase-dependent pathways have been found to link Eph receptor forward signaling to Rho activation ([@bib44]; [@bib45]; [@bib62]). Eph kinase-independent signaling can also lead to cell repulsion and segregation ([@bib76]) and can activate Rho, for example through binding of Dishevelled to the PDZ domain binding motif of Eph receptors ([@bib75]). Such kinase-independent signaling leads to a less sustained cell repulsion response than occurs when Eph kinase function is intact ([@bib76]). Taken together, these findings reveal some functional overlap between kinase- and PDZBD-dependent signaling, with a greater role of Eph kinase-activated pathways both in cell segregation and boundary cell induction.

Previous studies had not resolved whether boundary cells form on one or both sides of the interface of hindbrain segments. We find that for r3 and r5 they form on one side of each interface, in the *epha4*-expressing cells, and this is because they are induced by forward and not by reverse signaling. This finding is consistent with evidence that although reverse signaling can trigger cell repulsion, forward signaling leads to much stronger cell repulsion and actomyosin contraction and thus has a dominant role in cell segregation and border sharpening ([@bib6]; [@bib23]; [@bib59]; [@bib68]; [@bib69]; [@bib76]; [@bib89]). However, *rfng* expression is also detected in some cells adjacent to r3 or r5 that are not expressing *epha4*, in particular at the r5/r6 border. The finding that such expression adjacent to r3 and r5 does not occur in *epha4^Δ651^* or *epha4^KD^* mutants argues against the possibility that any MLC phosphorylation induced by reverse signaling upregulates boundary marker expression. An alternative explanation is that *rfng*-expressing cells in r6 derive from intermingling of boundary cells across the segment border. This explanation requires that *epha4* expression is downregulated in r5 cells that intermingle into adjacent segments, and indeed recent work has found dynamic regulation of r3 and r5 cell identity following intermingling ([@bib1]).

The decrease in boundary marker expression in *epha4* mutants is partially rescued by *mypt1* knockdown, suggesting that there is residual activation of myosin II at specific borders, perhaps due to other Eph-ephrin pairs. Intriguingly, the r5/r6 boundary was not rescued in *epha4* null mutants, but was in *epha4^KD^* and *epha4^Δ651^* mutants. Since the *epha4^Δ651^* mutant lacks forward but not reverse signaling, whereas the *epha4* null mutant lacks both, this could suggest that reverse signaling into r6 cells can induce boundary marker expression when tension is amplified by *mypt1* knockdown. Indeed, although forward signaling underlies actomyosin contraction in border sharpening, it remains possible that reverse signaling also leads to MLC phosphorylation, which can lead to boundary marker expression when increased by *mypt1* knockdown. However, *rfng* expression spreads into r5 but not r6 after *mypt1* knockdown, arguing against this idea. As some EphA and EphB receptors can form heteromers ([@bib26]), an alternative explanation is that truncated or kinase-dead EphA4 enables activation of another Eph receptor by ephrinB3. Indeed, EphB4, which has a low affinity for ephrinB3 ([@bib58]), is expressed in r5 and r6 and regulates cell segregation ([@bib15]).

Intriguingly, *mypt1* knockdown leads to spreading of *rfng* expression into r3 and r5, several cell diameters away from the segment border, whereas EphA4 is assumed to be activated at the border. One potential explanation is suggested by the finding that during liver development ephrin-expressing cells extend processes into Eph-expressing territory and thus regulate cell behaviour away from the border ([@bib8]). If this also occurs in the hindbrain, it could lead to weak EphA4 activation a few cell diameters from the border, which can upregulate *rfng* expression when tension is amplified by *mypt1* knockdown. Another possible mechanism is through secretion of ephrin-containing exosomes, which have been detected in cell culture ([@bib32]), though it is not known whether exosomes mediate ephrin signaling in vivo.

Regulation of cell identity by Taz activity {#s3-2}
-------------------------------------------

There is increasing evidence for roles of Yap/Taz activity in maintaining stem cells, or in some tissues in promoting their differentiation to specific derivatives ([@bib50]; [@bib55]; [@bib61]; [@bib83]). In some contexts, nuclear translocation of Yap/Taz protein is regulated by forces originating from interaction of cells with extracellular matrix, from stretching, shearing and compression of cells, and from actomyosin contractility within the cell ([@bib21]; [@bib37]; [@bib53]; [@bib74]; [@bib83]). Hindbrain boundary cells are neural progenitors that are prevented from differentiating through Notch activation, which is promoted by Rfng ([@bib13]), thus maintaining the boundary signaling centre ([@bib77]). Activation of Taz by actomyosin contraction therefore leads to the formation and maintenance of these specialised progenitors in part through regulation of Notch pathway activity. Likewise, an interplay between Yap/Taz and the Notch pathway that maintains progenitors has been found in other tissues (reviewed by [@bib81]). For example, Yap/Taz maintains epidermal stem cells by inhibiting Notch signaling through regulation of Notch pathway components ([@bib80]). In another example, the contractility of muscle cells activates Yap, which upregulates Jag2 expression, leading to Notch activation in neighbours that inhibits their differentiation ([@bib22]).

Yap and Taz also have important roles in growth control in which genes that drive proliferation are upregulated by nuclear localisation of Yap/Taz, which is inhibited by activation of the Hippo pathway ([@bib30]; [@bib38]; [@bib53]). Since cortical tension leads to nuclear localisation of Taz at hindbrain boundaries, this raises the question of whether actomyosin contraction increases cell proliferation in addition to inducing boundary marker expression. Studies in chick argue against this idea as hindbrain boundaries have a lower proliferation rate than segment centres ([@bib34]; [@bib63]), reflecting their role as a pool of neurogenic stem cells. However, recent work has found two-fold greater proliferation at boundaries than segment centres at late stages in the zebrafish hindbrain (after 26 hpf), which depends upon Yap/Taz and Tead activity ([@bib84]). Importantly, this work found that the Yap/Taz-Tead pathway is activated by actomyosin tension at boundaries and therefore increases cell proliferation downstream of Eph-ephrin signaling. Yap/Taz activation and cell proliferation declines by 40 hpf, concommitant with a switch of boundary cells to neurogenesis ([@bib84]). However, since this study used reporters that detected Tead activity only after 20 hpf, it did not test an earlier role in boundary cell specification, which we find occurs prior to 18 hpf. Taken together, these findings suggest stage-specific functions of Yap/Taz activity in cell specification and proliferation at hindbrain boundaries.

Concluding perspectives {#s3-3}
-----------------------

The mechanical regulation of gene expression enables an interplay between morphogenesis and cell identity that contributes to tissue patterning ([@bib11]; [@bib47]; [@bib90]). The transcriptional control of cell differentiation leads to differential expression of mediators of morphogenesis, creating mechanical forces which can in turn feed back on the specification of cell identity. In the hindbrain, *epha4* expression is regulated by *krox20* ([@bib78]), such that cell segregation and border sharpening is coupled to segmental identity ([@bib82]). Mechanical forces regulated by EphA4 signaling in turn lead to the specification of boundary cell fate, thus ensuring correct organisation of signaling centres. There is increasing evidence for roles of Eph receptors and ephrins in the regulation of cell differentiation through a diversity of pathways ([@bib51]; [@bib88]). In some cases, Eph receptor activation seems to be deployed to only regulate cell differentiation, by acting through pathways distinct from those that underlie cell segregation. For example, Eph activation regulates cell fate choices in Ciona by antagonising Fgf signaling through inhibition of the MAPK pathway ([@bib64]; [@bib73]). It will be important to understand how Eph signaling has these distinct functions in cell segregation and regulation of cell differentiation in different contexts. It will also be interesting to determine whether it has broader roles in activating the Yap/Taz pathway to couple border formation and the control of cell identity. In particular, it may be fruitful to explore this in vertebrate development, in which Eph signaling underlies the formation and maintenance of sharp borders in many tissues ([@bib4]; [@bib7]; [@bib25]). Since the principal mechanisms that drive border sharpening are contact repulsion and cortical tension that require actomyosin contraction ([@bib6]; [@bib23]; [@bib59]; [@bib68]; [@bib69]; [@bib76]), this raises the question as to whether the pathway uncovered here in the hindbrain is deployed in other tissues to regulate gene expression through Yap/Taz activation.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                  Designation                                                   Source or reference                                                      Identifiers                                                      Additional\
  (species) or resource                                                                                                                                                                                                                  information
  ------------------------------ ------------------------------------------------------------- ------------------------------------------------------------------------ ---------------------------------------------------------------- ----------------------------------------------------------------------------
  Recombinant\                   rfng (zebrafish, *Danio rerio*) in situ hybridisation probe   [@bib13], PMID:\                                                                                                                          
  DNA reagent                                                                                  [15068793](https://www.ncbi.nlm.nih.gov/pubmed/15068793)                                                                                  

  Recombinant DNA reagent        wnt1 (zebrafish) in situ hybridisation probe                  [@bib56], PMID: [2009859](https://www.ncbi.nlm.nih.gov/pubmed/2009859)                                                                    

  Recombinant DNA reagent        sema3gb (zebrafish) in situ hybridisation probe               [@bib77], PMID:\                                                                                                                          
                                                                                               [22764046](https://www.ncbi.nlm.nih.gov/pubmed/22764046)                                                                                  

  Recombinant DNA reagent        egr2b (zebrafish) in situ hybridisation probe                 [@bib60], PMID:\                                                                                                                          
                                                                                               [8464695](https://www.ncbi.nlm.nih.gov/pubmed/8464695)                                                                                    

  Sequence-based reagent         rfng (zebrafish) HCR probe                                    Molecular Instruments                                                                                                                     Designed and supplied by Molecular Instruments

  Sequence-based reagent         wnt1 (zebrafish) HCR probe                                    Molecular Instruments                                                                                                                     Designed and supplied by Molecular Instruments

  Sequence-based reagent         epha4 (zebrafish) HCR probe                                   Molecular Instruments                                                                                                                     Designed and supplied by Molecular Instruments

  Antibody                       anti-pMLC (rabbit polyclonal)                                 Cell Signalling Technology                                               Cat \# 3671\                                                     1:200
                                                                                                                                                                        RRID:[AB_330248](https://scicrunch.org/resolver/AB_330248)       

  Antibody                       anti-Taz (rabbit monoclonal)                                  Cell Signalling Technology                                               Cat \# D24E4\                                                    1:200
                                                                                                                                                                        RRID:[AB_10950494](https://scicrunch.org/resolver/AB_10950494)   

  Antibody                       anti-EphA4 (rabbit\                                           [@bib42], PMID:\                                                                                                                          1:450
                                 polyclonal)                                                   [8575627](https://www.ncbi.nlm.nih.gov/pubmed/8575627)                                                                                    

  Chemical compound, drug        phalloidin-atto 647N                                          Sigma-Aldrich                                                            Cat \# 65906                                                     1:250

  Chemical compound, drug        blebbistatin                                                  Sigma-Aldrich                                                            Cat \# B0560                                                     12.5 μM

  Chemical compound, drug        latrunculinB                                                  Sigma-Aldrich                                                            Cat \# 428020                                                    50 nM

  Sequence-based reagent         morpholino to block mypt1                                     [@bib36], PMID:\                                                                                                                          ATTTTTTGTGACTTACTCAGCGATG
                                                                                               [20147380](https://www.ncbi.nlm.nih.gov/pubmed/20147380)                                                                                  

  Sequenced-based reagent        morpholino to block taz                                       [@bib40], PMID:\                                                                                                                          CTGGAGAGGATTACCGCTCATGGTC
                                                                                               [16099986](https://www.ncbi.nlm.nih.gov/pubmed/16099986)                                                                                  

  Gequenced-based reagent        morpholino to block yap1                                      [@bib71], PMID:\                                                                                                                          AGCAACATTAACAACTCACTTTAGG
                                                                                               [19439659](https://www.ncbi.nlm.nih.gov/pubmed/19439659)                                                                                  

  Genetic reagent (*D. rerio*)   epha4a null mutant                                            This study                                                                                                                                Sequence in\
                                                                                                                                                                                                                                         [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}

  Genetic reagent (*D. rerio*)   epha4a Δ651 mutant                                            This study                                                                                                                                Sequence in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}

  Genetic reagent (*D. rerio*)   epha4a KD mutant                                              This study                                                                                                                                Sequence in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}

  Genetic reagent (*D. rerio*)   epha4a ΔPDZBD mutant                                          This study                                                                                                                                Sequence in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}

  Sequence-based reagent         genomic target of gRNA to create epha4a null mutant           This study                                                                                                                                GGCTGATGAAAGCTTCACGC

  Sequence-based reagent         forward primer to screen for epha4a null mutant               This study                                                                                                                                GCTCCGCAGTACATTTTAGGG

  Sequence-based reagent         reverse primer to screen for epha4a null mutant               This study                                                                                                                                GTCTTTCCTCTCACAGTGGGA

  Sequence-based reagent         genomic target of gRNA to create epha4a Δ651 mutant           This study                                                                                                                                GGAAAGCGTGAGATCTGTG

  Sequence-based reagent         forward primer to screen for epha4a Δ651 mutant               This study                                                                                                                                CCCTTCACATACGAGGACCCC

  Sequence-based reagent         reverse primer to screen for epha4a Δ651 mutant               This study                                                                                                                                GCTCGCTCACATTCAACACA

  Sequence-based reagent         genomic target of gRNA to create epha4a KD mutant             This study                                                                                                                                GGAAAGCGTGAGATCTGTG

  Sequence-based reagent         Donor oligonucleotide to create epha4a KD mutant              This study                                                                                                                                AAGATGCCTGGAAAGCGTGAaATtTGcGTGGCCATAAAAACCCTAAtGGCAGGgTACACCGACAAGCAAAGGCG

  Sequence-based reagent         forward primer to screen for epha4a KD mutant                 This study                                                                                                                                CCCTTCACATACGAGGACCCC

  Sequence-based reagent         reverse primer to screen for epha4a KD mutant                 This study                                                                                                                                GCTCGCTCACATTCAACACA

  Sequence-based reagent         genomic target of gRNA to create epha4a ΔPDZBD mutant         This study                                                                                                                                GCAGCAAATGCAGGACAGGA

  Sequence-based reagent         forward primer to screen for epha4a ΔPDZBD mutant             This study                                                                                                                                AGTTCTCCCCCTCAAACAAAA

  Sequence-based reagent         reverse primer to screen for epha4a ΔPDZBD mutant             This study                                                                                                                                CAGTACAGCGCTAAACGATCC

  Sequence-based reagent         genomic targets of gRNAs to create deletions in mypt1         This study                                                                                                                                GGTACGGTACGAAAGAGAGG\
                                                                                                                                                                                                                                         ACGAAGGTGAAGTTCGACGA\
                                                                                                                                                                                                                                         GGAACGAGCAGTTAAAGCGC\
                                                                                                                                                                                                                                         CTGCTCGAGCGGAGACACGG\
                                                                                                                                                                                                                                         TGGCGGACGCCAAGCAGAAG

  Sequence-based reagent         forward primer to screen for deletions in mypt1               This study                                                                                                                                CGACGTAACCAGGTTTGTTCA

  Sequence-based reagent         reverse primer to screen for deletions in mypt1               This study                                                                                                                                ACATTGGCGTAGTTGATGTCG

  Sequence-based reagent         genomic targets of gRNAs to create deletions in yap1          This study                                                                                                                                CTCAACCTCATCGGCACGGA\
                                                                                                                                                                                                                                         CCCGAACATGGACGATCTGG\
                                                                                                                                                                                                                                         AAGAGCCTCCAGATCGGTCT

  Sequence-based reagent         forward primer to screen for deletions in yap1                This study                                                                                                                                GCCGGACACAGAACATCTTTT

  Sequence-based reagent         reverse primer to screen for deletions in yap1                This study                                                                                                                                CTGTTTGTGGTTTCTGAGGGG

  Sequence-based reagent         genomic targets of gRNAs to create deletions in taz           This study                                                                                                                                CAAAGACCTGGACACGGATC\
                                                                                                                                                                                                                                         GAGATGGCCTTCACCCCCAA\
                                                                                                                                                                                                                                         GGAGACTCCACTCCCACACC

  Sequence-based reagent         forward primer to screen for deletions in taz                 This study                                                                                                                                AAAACTCTCCAAACTCCACGC

  Sequence-based reagent         reverse primer to screen for deletions in taz                 This study                                                                                                                                CCGTGTTCAATACTCATTCCCC

  Sequence-based reagent         genomic targets of gRNAs to create deletions in tead1a        This study                                                                                                                                TAAGCCCATGGACAATGACG\
                                                                                                                                                                                                                                         TGACATTGAGCAGAGCTTTC\
                                                                                                                                                                                                                                         CATTCTCTCAATGTCCTCCC

  Sequence-based reagent         forward primer to screen for deletions in tead1a              This study                                                                                                                                GTCAGTGTGCCTTGAGTTCTC

  Sequence-based reagent         reverse primer to screen for deletions in tead1a              This study                                                                                                                                ATTTTGCCCTCATCAGACAGG

  Sequence-based reagent         genomic targets of gRNAs to create deletions in tead3         This study                                                                                                                                CATTGAACAAAGCTTCCAGG\
                                                                                                                                                                                                                                         CTGAGAGGATGATCTTTCTG\
                                                                                                                                                                                                                                         ATGGACAAAACCGGAATGGA

  Sequence-based reagent         forward primer to screen for deletions in tead3               This study                                                                                                                                GAGCCGCCACCATTGCAG

  Sequence-based reagent         reverse primer to screen for deletions in tead3               This study                                                                                                                                TAGCTCTGACTAACGTGGGTG

  Sequence-based reagent         RVD sequences of ephrinb3b TALENs                             This study                                                                                                                                Left: NG HD NN NN NN NN NI NG NG NG HD NI NI NI NG NN NN HD\
                                                                                                                                                                                                                                         Right: HD NI NN NN NI NN NI NI NG NG HD HD HD NI NI NG HD HD NI NG
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Maintenance of zebrafish strains {#s4-1}
--------------------------------

Zebrafish embryos were raised at 28.5°C as described ([@bib87]). Embryos were staged according to morphological criteria ([@bib48]).

Morpholino knockdown {#s4-2}
--------------------

Antisense morpholino oligonucleotides (Gene Tools) were injected into one-cell-stage embryos. All injections were done in *p53* homozygote mutants or in combination with a *p53* morpholino to inhibit the off-target effects mediated by activation of pro-apoptotic pathways ([@bib31]; [@bib67]). The antisense morpholinos used were a splice-blocking morpholino against *mypt1* ([@bib36]) and *yap1* ([@bib71]), and a translation-blocking morpholino against *taz* ([@bib40]); the sequences are in the Key Resources Table. 4 ng of morpholino were injected in all cases except for MO-taz, for which 2.5 ng were injected. *mypt1* MO has the same effects on cell shape and increased pMLC as *mypt1* mutant embryos ([@bib36]). *yap1* MO has been validated by analysis of splicing and in rescue experiments ([@bib28]). taz MO leads to decreased Taz protein ([Figure 2---figure supplement 1G--H](#fig2s1){ref-type="fig"}). In addition, the phenotypic effects described in this study for MO-mediated knockdowns have been validated by generation and analysis of Crispr-mediated transient knockouts.

Pharmacological treatments {#s4-3}
--------------------------

Embryos were dechorionated and treated at the specified stages with 12.5 μM blebbistatin or 50 nM LatrunculinB in Danieau's solution. Embryos were fixed in 4% paraformaldehyde (PFA) and processed for immunostaining or in situ hybridization.

Generation of mutants {#s4-4}
---------------------

All injections were done in one-cell stage embryos. *ephrinb3b* mutants were generated using TALENs designed and constructed as previously outlined ([@bib9]). Plasmids used in the construction process (Golden Gate TALEN and TAL Effector Kit 1.0, \#1000000016) as well as pCS2TAL3-DD and pCS2TAL3-RR destination vectors (\#37275 and \#37276) ([@bib17]) were obtained from Addgene. TAL effector domains and FokI nuclease were cloned into these destination vectors to form the final pCS2-TAL vector for each TALEN, from which mRNA was synthesised using the SP6 mMessage mMachine kit (Life Technologies). Embryos were injected with equal amounts (100--300 pg) of RNA encoding each of the left and right TALEN arms. A founder with a frame shift (4 bp deletion and 2 bp insertion) that truncates the protein at residue five was used to raise the *ephrinb3b* mutant line. RVD sequences of *ephrinb3b* TALENs are in the Key Resources Table.

Point and truncated mutants of *epha4a* were generated by CRISPR/Cas9. For this, oligonucleotides targeting different *epha4a* sequences were cloned into the pDR274 plasmid for sgRNA production ([@bib41]; \#42250 Addgene). In vitro synthesis of the sgRNA was done using the T7 RiboMAX Large Scale RNA Production System (\#P1300 Promega). Embryos were injected with 200--300 pg gRNAs and 1.6 ng EnGen Cas9 protein (\#M0646M NEB). The target and gRNA sequences, and mutations generated, are given in the Key Resources Table and [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}. Immunostaining for EphA4 confirmed a complete absence of protein in homozygous null embryos.

To introduce the K658M mutation in the kinase domain of EphA4a, sgRNA and Cas9 protein were co-injected with a 74 bp donor oligonucleotide (Key Resources Table) containing three silent mutations at the gRNA target site, the K658M mutation and an additional silent mutation that generated an RsaI restriction site. Mutations were identified by amplicon restriction using restriction enzymes or T7 endonuclease I (\#M0302L NEB) and verified by sequencing. A fish was identified carrying the K658M mutation together with a 6 bp deletion affecting three additional residues (649-651) in the kinase domain.

For the transient CRISPR knockouts of *mypt1*, *yap1*, *taz*, *tead1a* and *tead3a*, 3 to 5 crRNAs targeting the same gene (Key resources table) were obtained from Integrated DNA Technologies Inc (IDT, Iowa, USA). crRNAs were annealed with equimolar amounts of tracRNA and 100 to 150 pg of each gRNA were co-injected with Cas9 protein. The generation of deletions was validated by PCR and in some cases by detection of mismatches by T7 endonuclease I digestion ([@bib3]) ([Figure 2---figure supplement 1B--F](#fig2s1){ref-type="fig"}).

Immunohistochemistry and in situ hybridization {#s4-5}
----------------------------------------------

For immunohistochemistry, embryos were fixed in 4% PFA for 2 hr and processed using standard methods. For anti-Taz stainings, antigen retrieval was carried out by heating fixed embryos at 90°C for 20 min in 150 mM Tris-HCl pH 9.5, which were then rinsed and treated with 0.025 U/ml DNAse1 for 75 min at 37°C prior to staining. Samples were imaged using a Leica SP5 confocal microscope. Antibodies against Taz and pMLC were from Cell Signalling Technology (\#D24E4 and 3671, respectively). Anti-EphA4 was described previously ([@bib42]). Actin was detected using phalloidin-atto 647N. Nuclear Taz staining was measured using Volocity software (Improvision) and statistical analysis carried out using unpaired two-tailed Student's t-test.

For in situ hybridization, embryos were fixed in 4% PFA overnight at 4°C and kept in methanol at −20°C prior to processing. The probes used have been previously described: *egr2b* ([@bib60]), *rfng* ([@bib13]), *wnt1* ([@bib56]), *sema3gb* ([@bib77]). Digoxigenin-UTP labelled riboprobes were synthesised and in situ hybridization performed as previously described ([@bib91]). After BCIP/NBT color development, embryos were re-fixed, cleared in 70% glycerol/PBS, and mounted for imaging using a Zeiss Axioplan2 with Axiocam HRc camera. In some experiments, *rfng, wnt1* and *epha4a* transcripts were detected by hybridization chain reaction (HCR) using reagents obtained from Molecular Instruments (In Situ HCR v3.0) and the method described by [@bib14].
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Thank you for submitting your article \"Actomyosin regulation by Eph receptor signaling couples boundary cell formation to border sharpness\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Marianne Bronner as the Senior and Reviewing Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Filippo M Rijli (Reviewer \#1); Robb Krumlauf (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This interesting study by Cayuso et al. addresses ae long standing question of how border sharpening and boundary cell formation are coupled. By examining these events in the developing zebrafish hindbrain, they show that boundary cell markers are induced in EphA4-expressing cells and are up-regulated by forward signaling in rhombomeres 3 and 5. They show that myosin II phosphorylation downstream of EphA4 activation increases mechanical tension at segment borders, in turn inducing boundary cell markers via nuclear translocation of Taz.

Their work couples for the first time boundary sharpening by mechanical forces with the induction of boundary-specific genes, via EphA4 forward signaling. The findings are highly significant and novel. While the study is very well done, a few changes described below would improve the paper and render it ready for publication. The detailed reviews are included below for additional clarification.

Essential revisions:

1\) The Taz phenotype in *epha4^-/-^* at 16hpf presented in Figure 6D is currently not very convincing. The authors\' case would be strengthened by presenting the Taz phenotype in *epha4^-/-^* at 18hpf.

2\) Genotyping data for CRISPants should be added as well as validation of the effects of the MO on protein levels should be added.

3\) Regarding whether EphA4 forward signaling drives all the downstream actin rearrangement/Taz localization, the data suggests that this occurs via forward signaling, but are not conclusive. While adding data from a forward signaling mutant would be optimal, this is not essential but would ask that you soften this point by modifying text.

*Reviewer \#1:*

This elegant study addresses one long standing and elusive key question concerning rhombomere (r) compartment formation in the developing hindbrain, namely how border sharpening and boundary cell formation are coupled. Jordi Cayuso and colleagues now beautifully identify the underlying mechanism in the hindbrain of the zebrafish embryo. They show that, in r3 and r5, boundary cell markers are induced in *epha4*-expressing cells and are up-regulated by forward signaling. Moreover, they demonstrate that myosin II phosphorylation downstream of *epha4* activation increases mechanical tension at segment borders, which in turn results in induction of boundary cell markers via nuclear translocation of Taz. Thus, Eph signaling couples border sharpening with boundary cell formation through mechanotransduction and Taz/Tead nuclear regulation of gene expression. These findings provide very important novel insights and will be of great interest to the readers of *eLife*.

A critical demonstration linking *epha4* signaling to regulation of border gene expression by Taz-mediated mechanotransduction is provided in Figure 6. However, the presentation of data in Figure 6D (*epha4^-/-^*) must be improved. First, the stage of Figure 6D is not mentioned on the panel nor in the figure legend. I assume is 16phf, as in Figure 6B. If so, then the distribution/placement of the yellow arrowheads when comparing Figure 6B and D makes difficult to appreciate the described reduction in nuclear Taz at the affected boundaries. Maybe using asterisks in addition to yellow arrowheads could help. Also, as it might be difficult to fully appreciate the defect in Taz localization at the 16hpf stage, the authors may add a quantification of the results as they did for *MO-mypt1* in Figure 6I. Nonetheless, it appears that the nuclear localisation of Taz at boundaries at 16hpf is still not fully refined and may suffer from a certain variability, even among wild type embryos. In contrast, Taz expression pattern at boundaries is very clear at 18hpf, as in Figure 6C. I believe therefore the analysis would very much benefit from presenting the Taz phenotype in *epha4^-/-^* at 18hpf, which would further strengthen the authors\' case. Lastly, the stage in Figure 6E should be mentioned as well -- i.e. 18hpf, and Figure 6G, G\', H, H\' are not 14hpf but 18hpf.

*Reviewer \#2:*

This is a very interesting and comprehensive study which investigates the fundamental question of whether morphogenetic processes, associated with sharpening of inter-rhombomeric boundaries in the zebrafish hindbrain, are coupled with cell fate determination events that create unique boundary cells. They utilize gene editing to create an allelic series of EphA4 genes to clearly demonstrate that forward signaling from EphA4 is required to establish boundary cell identities and this process involves dual inputs of kinase and PDZ signaling. These experiments indicate that there is a tight coupling of boundary sharpening and formation of boundary cell identities regulated by EphA4.

While published studies from these authors and other have previously analyzed events and processes in boundary sharpening this study provides novel insight into mechanisms of cell fate determination modulated by EphA4 signaling that govern formation of boundary cell identity. They show that mechanical tension gated by phosphorylation of MLC directly impacts the regulation of boundary cell identity. This involves actomyosin dependent nuclear localization of Taz that regulates boundary cell. identity markers.

This a very strong paper because the authors elegantly show through genetic manipulations and cellular analyses precisely how the opposing domains of EphA4 and Efnb3 trigger a series of events that coordinates morphogenetic process of cell sharpening directly to cell differentiation. This is important because it provides a means for regulating the neural progenitor stem population at rhombomere boundaries. These findings have significant relevance beyond the formation hindbrain boundaries as this type of signaling is important in other contexts where cell sharpening and differentiation programs appear to correlate with EphA4 signaling.

The figures and data supporting the conclusions are very clear and beautifully presented. I believe this is very high quality work, with novel insight and broad general interest to cell and developmental biologists. My only comment is that I would have liked to have seen a summary/model that illustrates the steps in these processes. I believe it would help tie this together and reinforce the findings with the reader.

*Reviewer \#3:*

In this manuscript, Cayuso et al. report that forward activation of EphA4 via the kinase and PDZ domains leads to actomyosin phosphorylation and actin contraction at segment borders, which in turn increases nuclear localization of Taz that induces the expression of boundary markers by interacting with Tead1a. This is a very interesting work, which couples for the first time boundary sharpening by mechanical forces with the induction of boundary-specific genes, via EphA4 forward signaling. These findings are significant and novel. Therefore, in principal I fully support its publication in *eLife*. Yet, there are some weaknesses in the data that should be addressed prior to its acceptance.

\- The study uses many types of KO and KD techniques to eliminate the expression of multiple genes. However, no demonstration of the genotypes of the Crisp-Cas lines/Crispr-Cas transiently injected embryos as well as the loss of protein expression in the MO-injected embryos is provided to support the genetic and/or expression loss of the desired sequence/protein. These validations are necessary in the manuscript.

\- A general EphA4 KO led to loss of pMLC in r2/r3, r3/r4 r5/r6 borders, as well as prevented the nuclear localization of Taz. However, there is no confirmation that these effects occur via the forward signaling only. Although the authors showed that the border expression of *rfng* and *wnt* is induced by the forward signaling of EphA4, these data are not sufficient to conclude that the entire pathway upstream to *rfng* expression is mainly mediated through the forward signaling. Only by using of the different EphA4 mutants in additional levels the pathway the authors can argue that the mechanical stabilization and Taz nuclear localization in the borders is mediated via the forward signaling.

\- The authors don\'t show the pattern of the actin cables/pMLC in the *mypt1* KO. This is necessary in order to fully support the suggested model. Moreover, also in the rescues it would be nice to show not only the *rfng* expression rescue but the actual rescue if the actin cables/pMLC, as these are the actual readouts of the mechanical forces induced by EphA4.

\- Taz KO/KD leads to loss of *rfng* in all boundaries, even in those not affected by *epha4* KO. Moreover, Tead1a KO leads to loss of *rfng* in a much milder way than Taz KO. These findings have to be explained in view of the suggested model of activation.

\- The quality of the data in Figure 6 is poor. The nuclear localization data of Taz upon the different manipulations are hard to evaluate by the DAPI+ immunostaining. This is a very significant part of the study, and the authors have to present the cytoplasm-to-nuclear localization in a better way.

10.7554/eLife.49696.018

Author response

> Essential revisions:
>
> 1\) The Taz phenotype in epha4^-/-^ at 16hpf presented in Figure 6D is currently not very convincing. The authors\' case would be strengthened by presenting the Taz phenotype in epha4^-/-^ at 18hpf.

We have repeated the immunostainings at 18 hpf and present better data. We now also show examples of nuclear localisation in different boundaries in Figure 6---figure supplement 1. We have clarified that there is an increase in Taz levels at boundaries, consistent with evidence that the actin cytoskeleton can regulate the stability as well as nuclear localisation of Taz (subsection "Myosin regulation downstream of EphA4 regulates Taz localization", first paragraph). Not all boundary cells have nuclear Taz, which may reflect dynamic nuclear localisation.

> 2\) Genotyping data for CRISPants should be added as well as validation of the effects of the MO on protein levels should be added.

We now present these data in Figure 2---figure supplement 1 and describe our and previous validations of MOs in Materials and methods (subsection "Generation of mutants"). All phenotypes from MO knockdowns have been validated by Crispr-mediated knockout. We discuss this in more detail in the response to reviewer 3.

> 3\) Regarding whether EphA4 forward signaling drives all the downstream actin rearrangement/Taz localization, the data suggests that this occurs via forward signaling, but are not conclusive. While adding data from a forward signaling mutant would be optimal, this is not essential but would ask that you soften this point by modifying text.

This is a good point, as analysing Taz localisation in the different mutants would test whether it correlates with boundary cell formation. We have now analysed Taz localisation in the forward signaling mutants (truncated and kinase dead EphA4) and find that the same boundaries are disrupted as in the null mutant.

> Reviewer \#1:
>
> \[...\] A critical demonstration linking epha4 signaling to regulation of border gene expression by Taz-mediated mechanotransduction is provided in Figure 6. However, the presentation of data in Figure 6D (epha4^-/-^) must be improved. First, the stage of Figure 6D is not mentioned on the panel nor in the figure legend. I assume is 16phf, as in Figure 6B. If so, then the distribution/placement of the yellow arrowheads when comparing Figure 6B and D makes difficult to appreciate the described reduction in nuclear Taz at the affected boundaries. Maybe using asterisks in addition to yellow arrowheads could help. Also, as it might be difficult to fully appreciate the defect in Taz localization at the 16hpf stage, the authors may add a quantification of the results as they did for MO-mypt1 in Figure 6I. Nonetheless, it appears that the nuclear localisation of Taz at boundaries at 16hpf is still not fully refined and may suffer from a certain variability, even among wild type embryos. In contrast, Taz expression pattern at boundaries is very clear at 18hpf, as in Figure 6C. I believe therefore the analysis would very much benefit from presenting the Taz phenotype in epha4^-/-^ at 18hpf, which would further strengthen the authors\' case. Lastly, the stage in Figure 6E should be mentioned as well -- i.e. 18hpf, and Figure 6G, G\', H, H\' are not 14hpf but 18hpf.

These are good points. We have repeated the immunostainings at 18 hpf and present better data. We now also show examples of nuclear localisation in different boundaries in Figure 6---figure supplement 1. We have clarified (subsection "Myosin regulation downstream of EphA4 regulates Taz localization", first paragraph) that there is an increase in Taz levels at boundaries, consistent with evidence that the actin cytoskeleton can regulate the stability as well as nuclear localisation of Taz. Not all boundary cells have nuclear Taz, which may reflect dynamic nuclear localisation. We now mention the embryo stage for each panel on the figure and in the legend.

> Reviewer \#2:
>
> \[...\] My only comment is that I would have liked to have seen a summary/model that illustrates the steps in these processes. I believe it would help tie this together and reinforce the findings with the reader.

Thank you for these helpful ideas. We now include a summary model as Figure 7. We tried to provide a broader context on possible relevance to other tissues in the subsection "Concluding Perspectives", and we have now improved this section.

> Reviewer \#3:
>
> \[...\] There are some weaknesses in the data that should be addressed prior to its acceptance.
>
> \- The study uses many types of KO and KD techniques to eliminate the expression of multiple genes. However, no demonstration of the genotypes of the Crisp-Cas lines/Crispr-Cas transiently injected embryos as well as the loss of protein expression in the MO-injected embryos is provided to support the genetic and/or expression loss of the desired sequence/protein. These validations are necessary in the manuscript.

We now include our data for the deletions in transient gene knockouts and the relevant sequence information for mutants (Figure 2---figure supplement 1). The MOs used have previously been described and validated by others -- we now make this clearer in the Materials and methods (subsection "Generation of mutants"). For all MO-mediated knockdowns, we also carried out transient Crispr-mediated knockouts to ascertain whether this leads to the same phenotype. When possible, we validated the effect of MO on protein level. We show that the Taz MO (Hong et al., 2005) leads to a decreased level of protein expression (Figure 2---figure supplement 1). For the *mypt1* MO, there is to our knowledge no antibody available to detect the zebrafish protein. *mypt1* MO and mutant embryos were previously shown (Gutzman and Sive, 2010) to alter cell shape and to increase phosphorylation of MLC, which is a target of Mypt1. Likewise, we find that *mypt1* morphant and mutant embryos have the same phenotype (increased boundary marker expression). The *yap1* MO has been validated by Fukui et al. (2014) by rescue and by analysis of splicing, and also used by Cebola et al., Nat Cell Biol 17, 615-626, 2015; Agarwala et al., *eLife* e08201, 2015; Kozlovskaja-Gumbriene et al., *eLife* e21049, 2017.

> \- A general EphA4 KO led to loss of pMLC in r2/r3, r3/r4 r5/r6 borders, as well as prevented the nuclear localization of Taz. However, there is no confirmation that these effects occur via the forward signaling only. Although the authors showed that the border expression of rfng and wnt is induced by the forward signaling of EphA4, these data are not sufficient to conclude that the entire pathway upstream to rfng expression is mainly mediated through the forward signaling. Only by using of the different EphA4 mutants in additional levels the pathway the authors can argue that the mechanical stabilization and Taz nuclear localization in the borders is mediated via the forward signaling.

We have now analysed Taz localisation in the forward signaling mutants (truncated and kinase dead EphA4) and find that the same boundaries are disrupted as in the null mutant. As we have not analysed pMLC in the forward signaling mutants, we have softened our discussion of this point (subsection "EphA4 signaling and boundary cell formation"). A number of studies have shown that forward signaling is the main driver of segregation and border sharpening, and acts by increasing actomyosin tension (Canty et al., 2017; Fagotto et al., 2013; O'Neill et al., 2016; Rohani et al., 2011, 2014). However, we have shown in a cell culture model that reverse signaling leads to weaker repulsion that can contribute to cell segregation (Taylor et al., 2017; Wu et al., 2019). Nevertheless, if reverse signaling does lead to some increase in pMLC at boundaries, this is not sufficient to induce boundary gene expression in forward signaling mutants, even after amplifying tension by *mypt1* knockdown.

> \- The authors don\'t show the pattern of the actin cables/pMLC in the mypt1 KO. This is necessary in order to fully support the suggested model. Moreover, also in the rescues it would be nice to show not only the rfng expression rescue but the actual rescue if the actin cables/pMLC, as these are the actual readouts of the mechanical forces induced by EphA4.

We do not show the increase in MLC phosphorylation after *mypt1* knockdown as this had been shown by Gutzman and Sive (2010) by Western blot analysis and immunostaining of the hindbrain. They were not able to detect pMLC at hindbrain boundaries in wild type embryos, but did when pMLC increases in the *mypt1* mutant. Their Western blot analysis revealed a five-fold increase in pMLC after *mypt1* knockdown. By optimising the immunostaining we were able to detect pMLC at hindbrain boundaries in wild type embryos. This extends the previous findings of myosin and actin cables at boundaries, which Calzolari et al. (2014) showed are EphA4-dependent. We agree that it would be nice to show that *mypt1* knockdown increases pMLC at boundaries in the EphA4 mutant, but feel that our findings together with the published work give compelling evidence for the pathway from EphA4 --\> pMLC --\> Taz --\> boundary gene expression.

> \- Taz KO/KD leads to loss of rfng in all boundaries, even in those not affected by epha4 KO. Moreover, Tead1a KO leads to loss of rfng in a much milder way than Taz KO. These findings have to be explained in view of the suggested model of activation.

We have clarified these points in the revised manuscript (subsection "*taz* and *tead1a* are required for boundary marker expression"). That Taz knockout affects all hindbrain boundaries is consistent with increased pMLC and Taz nuclear localisation at all segment borders. EphB4 and ephrinB2 are segmentally expressed and drive cell segregation, and likely contribute to pMLC and boundary marker expression at the r1/r2, r5/r6 and r6/r7 borders that are not affected in the EphA4 mutants (mentioned in the Introduction and Results). However, we have found that there is some redundancy at these borders, and that at least one further Eph-ephrin pair is segmentally expressed. We now mention (see the aforementioned subsection) that the milder phenotype of tead1a knockout may be due to partial redundancy with family members that have not yet been analysed.

> \- The quality of the data in Figure 6 is poor. The nuclear localization data of Taz upon the different manipulations are hard to evaluate by the DAPI+ immunostaining. This is a very significant part of the study, and the authors have to present the cytoplasm-to-nuclear localization in a better way.

We agree that the quality of the staining is not great, which unfortunately reflects that the Taz antibody is tricky to use. For example, Voltes et al. (2019) analysed later stages and detected increased Taz protein but not its nuclear localisation at boundaries (they obtained indirect evidence for pathway activation by using a Tead reporter gene). We tested different conditions and found that it is important to carry out antigen retrieval (now mentioned in the subsection "Immunohistochemistry and in situ hybridization"). We have carried out stainings for *epha4* null, truncated and kinase dead mutants and present the new data (revised Figure 6). We also clarified (subsection "Myosin regulation downstream of EphA4 regulates Taz localization", first paragraph) that there is an increase in Taz levels at boundaries, consistent with evidence that the actin cytoskeleton can regulate the stability of Taz. Not all boundary cells have nuclear Taz, which may reflect dynamic nuclear localisation. We now show examples of nuclear localisation in different boundaries (Figure 6---figure supplement 1).
